Literature DB >> 29108941

Both hyper- and hypo-activation to cognitive challenge are associated with increased beta-amyloid deposition in healthy aging: A nonlinear effect.

Chris M Foster1, Kristen M Kennedy1, Marci M Horn1, David A Hoagey1, Karen M Rodrigue2.   

Abstract

Beta-amyloid (Aβ) positive individuals hyper-activate brain regions compared to those not at-risk; however, hyperactivation is then thought to diminish as Alzheimer's disease symptomatology begins, evidencing eventual hypoactivation. It remains unclear when in the disease staging this transition occurs. We hypothesized that differential levels of amyloid burden would be associated with both increased and decreased activation (i.e., a quadratic trajectory) in cognitively-normal adults. Participants (N = 62; aged 51-94) underwent an fMRI spatial distance-judgment task and Amyvid-PET scanning. Voxelwise regression modeled age, linear-Aβ, and quadratic-Aβ as predictors of BOLD activation to difficult spatial distance-judgments. A significant quadratic-Aβ effect on BOLD response explained differential activation in bilateral angular/temporal and medial prefrontal cortices, such that individuals with slightly elevated Aβ burden exhibited hyperactivation whereas even higher Aβ burden was then associated with hypoactivation. Importantly, in high-Aβ individuals, Aβ load moderated the effect of BOLD activation on behavioral task performance, where in lower-elevation, greater deactivation was associated with better accuracy, but in higher-elevation, greater deactivation was associated with poorer accuracy during the task. This study reveals a dose-response, quadratic relationship between increasing Aβ burden and alterations in BOLD activation to cognitive challenge in cognitively-normal individuals that suggests 1) the shift from hyper-to hypo-activation may begin early in disease staging, 2) depends, in part, on degree of Aβ burden, and 3) tracks cognitive performance.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Beta-amyloid; Cognition; Nonlinear BOLD activation; Preclinical Alzheimer's disease; fMRI

Mesh:

Substances:

Year:  2018        PMID: 29108941      PMCID: PMC5747976          DOI: 10.1016/j.neuroimage.2017.10.068

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  42 in total

1.  Categorical and coordinate spatial relations: fMRI evidence for hemispheric specialization.

Authors:  M Baciu; O Koenig; M P Vernier; N Bedoin; C Rubin; C Segebarth
Journal:  Neuroreport       Date:  1999-04-26       Impact factor: 1.837

Review 2.  Potential of functional MRI as a biomarker in early Alzheimer's disease.

Authors:  Reisa Sperling
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

3.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 4.  Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

5.  β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.

Authors:  K M Rodrigue; K M Kennedy; M D Devous; J R Rieck; A C Hebrank; R Diaz-Arrastia; D Mathews; D C Park
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

6.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

7.  Aβ Deposition in aging is associated with increases in brain activation during successful memory encoding.

Authors:  Elizabeth C Mormino; Michael G Brandel; Cindee M Madison; Shawn Marks; Suzanne L Baker; William J Jagust
Journal:  Cereb Cortex       Date:  2011-09-23       Impact factor: 5.357

8.  BDNF val66met polymorphism affects aging of multiple types of memory.

Authors:  Kristen M Kennedy; Elizabeth D Reese; Marci M Horn; April N Sizemore; Asha K Unni; Michael E Meerbrey; Allan G Kalich; Karen M Rodrigue
Journal:  Brain Res       Date:  2014-09-28       Impact factor: 3.252

9.  Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline.

Authors:  J L O'Brien; K M O'Keefe; P S LaViolette; A N DeLuca; D Blacker; B C Dickerson; R A Sperling
Journal:  Neurology       Date:  2010-05-12       Impact factor: 9.910

10.  β-Amyloid Deposition Is Associated with Decreased Right Prefrontal Activation during Task Switching among Cognitively Normal Elderly.

Authors:  Hwamee Oh; Jason Steffener; Qolamreza R Razlighi; Christian Habeck; Yaakov Stern
Journal:  J Neurosci       Date:  2016-02-10       Impact factor: 6.167

View more
  8 in total

1.  Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women.

Authors:  Minjie Wu; Rebecca C Thurston; Dana L Tudorascu; Helmet T Karim; Chester A Mathis; Brian J Lopresti; M Ilyas Kamboh; Ann D Cohen; Beth E Snitz; William E Klunk; Howard J Aizenstein
Journal:  Neurobiol Aging       Date:  2018-12-01       Impact factor: 4.673

Review 2.  PET imaging of neural activity, β-amyloid, and tau in normal brain aging.

Authors:  Kai Zhang; Hiroshi Mizuma; Xiaohui Zhang; Kayo Takahashi; Chentao Jin; Fahuan Song; Yuanxue Gao; Yousuke Kanayama; Yuping Wu; Yuting Li; Lijuan Ma; Mei Tian; Hong Zhang; Yasuyoshi Watanabe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-05       Impact factor: 9.236

3.  Alzheimer's pathology targets distinct memory networks in the ageing brain.

Authors:  Anne Maass; David Berron; Theresa M Harrison; Jenna N Adams; Renaud La Joie; Suzanne Baker; Taylor Mellinger; Rachel K Bell; Kaitlin Swinnerton; Ben Inglis; Gil D Rabinovici; Emrah Düzel; William J Jagust
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

Review 4.  Neuroimaging Modalities in Alzheimer's Disease: Diagnosis and Clinical Features.

Authors:  JunHyun Kim; Minhong Jeong; Wesley R Stiles; Hak Soo Choi
Journal:  Int J Mol Sci       Date:  2022-05-28       Impact factor: 6.208

5.  Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.

Authors:  Willem Huijbers; Aaron P Schultz; Kathryn V Papp; Molly R LaPoint; Bernard Hanseeuw; Jasmeer P Chhatwal; Trey Hedden; Keith A Johnson; Reisa A Sperling
Journal:  J Neurosci       Date:  2018-11-27       Impact factor: 6.167

6.  Increasing beta-amyloid deposition in cognitively healthy aging predicts nonlinear change in BOLD modulation to difficulty.

Authors:  Kristen M Kennedy; Chris M Foster; Karen M Rodrigue
Journal:  Neuroimage       Date:  2018-08-11       Impact factor: 6.556

Review 7.  Imaging biomarkers in neurodegeneration: current and future practices.

Authors:  Peter N E Young; Mar Estarellas; Emma Coomans; Meera Srikrishna; Helen Beaumont; Anne Maass; Ashwin V Venkataraman; Rikki Lissaman; Daniel Jiménez; Matthew J Betts; Eimear McGlinchey; David Berron; Antoinette O'Connor; Nick C Fox; Joana B Pereira; William Jagust; Stephen F Carter; Ross W Paterson; Michael Schöll
Journal:  Alzheimers Res Ther       Date:  2020-04-27       Impact factor: 6.982

8.  Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease.

Authors:  Ornella V Billette; Gabriel Ziegler; Merita Aruci; Hartmut Schütze; Jasmin M Kizilirmak; Anni Richter; Slawek Altenstein; Claudia Bartels; Frederic Brosseron; Arturo Cardenas-Blanco; Philip Dahmen; Peter Dechent; Laura Dobisch; Klaus Fliessbach; Silka Dawn Freiesleben; Wenzel Glanz; Doreen Göerß; John Dylan Haynes; Michael T Heneka; Ingo Kilimann; Okka Kimmich; Luca Kleineidam; Christoph Laske; Andrea Lohse; Ayda Rostamzadeh; Coraline Metzger; Matthias H Munk; Oliver Peters; Lukas Preis; Josef Priller; Klaus Scheffler; Anja Schneider; Annika Spottke; Eike Jakob Spruth; Alfredo Ramirez; Sandra Röske; Nina Roy; Stefan Teipel; Michael Wagner; Jens Wiltfang; Steffen Wolfsgruber; Renat Yakupov; Peter Zeidman; Frank Jessen; Björn H Schott; Emrah Düzel; Anne Maass
Journal:  Neurology       Date:  2022-06-03       Impact factor: 11.800

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.